Latest News- Bispecific Antibodies For Cancer Market: CD19 or CD3 is expected to lead the Type segment during 2025-2029

The Bispecific Antibodies For Cancer Market is being driven by Increasing prevalence of cancer

The Bispecific Antibodies For Cancer Market is expected to grow at a CAGR of 6.9% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 338 million. Bispecific antibodies represent a groundbreaking development in cancer immunotherapy, offering potential advantages in the treatment of various cancer types. Companies such as Aptevo Therapeutics and Xencor are collaborating with industry leaders like Roche and Amgen to bring these innovative therapies to market. Amgen's BiTEs platform and MicroGenics' DART antibody platform have been instrumental in the development of bispecific antibodies. Genentech, a Roche subsidiary, has also contributed significantly with its CrossMAb technology, which facilitates specific binding of light and heavy chains, resulting in targeted molecular interactions in the antibody's short arm. These collaborations and technological advancements underscore the immense potential of bispecific antibodies in cancer therapy. 

Get more information on Bispecific Antibodies For Cancer Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Type
  • CD19 or CD3
  • CD30 or CD16A
• Distribution Channel
  • Hospitals
  • Retail pharmacies
  • Online
• Action Mechanism
  • Dual antigen targeting
  • Dual-blocking antibodies
  • T-cell engagers
• Therapeutic Area
  • Oncology
  • Autoimmune diseases
  • Infectious diseases
  • Neurological disorders
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
    • India
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increasing prevalence of cancer
• Advantages of bispecific antibodies over monoclonal antibodies
• Strong pipeline of bispecific antibodies

However, the market also witnesses some limitations, which are as follows:

• High cost of drugs
• Late diagnosis leads to poor survival rates
• Side effects of BLINCYTO

Benefits of Buying Global Bispecific Antibodies For Cancer Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Bispecific Antibodies For Cancer Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The bispecific antibodies market for adult Americans is experiencing significant growth, driven by the increasing demand for targeted therapies in cancer treatment. This market is valued at USD8 trillion, with multiple myeloma and other cancers being primary indications. Clinical trials for bispecific antibodies against mental health disorders, such as psoriasis, Crohn's disease, and multiple sclerosis, are also underway. However, challenges in the supply chain and diverted resources due to the COVID-19 pandemic may hinder market growth. Technological advancements in the production of bispecific antibodies, such as those represented by Tibulizumab and Ozoralizumab, are expected to mitigate these challenges and drive future growth in the biologic therapies sector.

Market Research Overview

The global biotechnology market encompasses businesses involved in the research and development or production of various biotech products, including biologics, biosimilars, bio-betters, and biotech reagents. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving market growth include an aging population, with the global population over 60 years projected to reach nearly one-quarter by 2050 in the US and Europe by 2030, and the ongoing research and development in chronic diseases such as cancer and autoimmune disorders, as well as infectious diseases.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/